No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials'☆

Autor: Harish V K Ratna, Subodh Kumar Pathak, Apurva Pandey, Abhijeet Ashok Salunke, Praveen Thivari, Vivek Menon, Kunal Nandy, Jalil Mujawar, Anant Dattatray Dhanwate, Sanjay Pandey, Jasneet Chawla
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Zdroj: Diabetes & Metabolic Syndrome
Diabetes & Metabolic Syndrome: Clinical Research & Reviews
ISSN: 1878-0334
1871-4021
Popis: Background and aims Coronavirus pandemic is currently a global public health emergency with no definitive treatment guidelines. We conducted a systematic review and meta-analysis of the literature evaluating the efficacy of hydroxychloroquine and its related formulations in COVID-19 patients. Methods A systematic search of PubMed, Scopus, MedRxiv data and Cochrane Central Register of Clinical Trials for published articles that reported the outcomes of COVID-19 patients treated with hydroxychloroquine or its compounds was done. We identified 1071 published studies and 7 studies were included in the analysis. Results The study population consisted of a total of 4984 patients, of which 1721 (34.5%) received hydroxychloroquine or its congeners (HCQ group) while 3091 (62.01%) received standard of care or had included antiviral medication (control group). The pooled estimate of successful treatment in the hydroxychloroquine group and the control group was 77.45% and 77.87% respectively, which indicated similar clinical outcomes in patients treated with hydroxychloroquine compared to the control group. The odds ratio of a favourable outcome with hydroxychloroquine was 1.11 (95 CI 0.72 to 1.69) (p = 0.20). The pooled risk difference of favourable outcome with hydroxychloroquine versus control group was 0.00 (95 CI -0.03 to 0.03) which was statistically not significant (p = 0.10). Conclusions: The present evidence shows no benefit of hydroxychloroquine in patients affected by mild to moderate COVID-19 disease. However, now several trials on HCQ are ongoing and hopefully more data will be available soon. Hence, the management of COVID-19 is set to change for better in the future.
Highlights • This meta-analysis includes only randomised controlled trials, with systematic review of recently published data. • Hydroxychloroquine has no benefit in treatment of mild to moderate COVID-19 disease. • Large size multi-centre studies are required for further evaluation.
Databáze: OpenAIRE
Externí odkaz: